Compare VTSI & CNTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VTSI | CNTB |
|---|---|---|
| Founded | 1993 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.0M | 135.7M |
| IPO Year | 1999 | 2020 |
| Metric | VTSI | CNTB |
|---|---|---|
| Price | $3.12 | $2.24 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $5.00 | ★ $8.67 |
| AVG Volume (30 Days) | 53.6K | ★ 287.7K |
| Earning Date | 05-11-2026 | 08-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $185,971.00 | $64,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.30 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $3.10 | $1.23 |
| 52 Week High | $7.47 | $3.82 |
| Indicator | VTSI | CNTB |
|---|---|---|
| Relative Strength Index (RSI) | 35.47 | 53.84 |
| Support Level | $3.18 | $2.03 |
| Resistance Level | $3.60 | $2.68 |
| Average True Range (ATR) | 0.15 | 0.18 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 17.68 | 92.31 |
VirTra Inc is a U.S.-based company that is engaged in the sale and development of judgmental use-of-force training simulators and firearms training simulators for law enforcement, military, and commercial uses. It sells simulators and related products across the globe through a direct sales force and international distribution partners. The services provided by the company include installation, training, limited warranties, service agreements, and related support. The company operates in six segments, which include Simulators and Accessories, Extended Service, Customized software and Custom content, Installation and Training, Design and Prototyping, and Subscription Training Equipment Partnership. The majority of its revenue is generated from the Simulators and Accessories segment.
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.